108 related articles for article (PubMed ID: 38815694)
1. Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer - A phase II study.
Weisz Ejlsmark M; Bahij R; Schytte T; Rønn Hansen C; Bertelsen A; Mahmood F; Bau Mortensen M; Detlefsen S; Weber B; Bernchou U; Pfeiffer P
Radiother Oncol; 2024 May; 197():110347. PubMed ID: 38815694
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study.
Bordeau K; Michalet M; Keskes A; Valdenaire S; Debuire P; Cantaloube M; Cabaillé M; Portales F; Draghici R; Ychou M; Assenat E; Mazard T; Samalin E; Gauthier L; Colombo PE; Carrere S; Souche FR; Aillères N; Fenoglietto P; Azria D; Riou O
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612004
[TBL] [Abstract][Full Text] [Related]
3. Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery.
Mazzola R; Fersino S; Aiello D; Gregucci F; Tebano U; Corradini S; Di Paola G; Cirillo M; Tondulli L; Ruffo G; Ruggieri R; Alongi F
Strahlenther Onkol; 2018 Sep; 194(9):835-842. PubMed ID: 29696321
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiation therapy for locally advanced pancreatic cancer.
Jung J; Yoon SM; Park JH; Seo DW; Lee SS; Kim MH; Lee SK; Park DH; Song TJ; Ryoo BY; Chang HM; Kim KP; Yoo C; Jeong JH; Kim SC; Hwang DW; Lee JH; Song KB; Jo YY; Park J; Kim JH
PLoS One; 2019; 14(4):e0214970. PubMed ID: 30978229
[TBL] [Abstract][Full Text] [Related]
5. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study.
Michalet M; Bordeau K; Cantaloube M; Valdenaire S; Debuire P; Simeon S; Portales F; Draghici R; Ychou M; Assenat E; Dupuy M; Gourgou S; Colombo PE; Carrere S; Souche FR; Aillères N; Fenoglietto P; Azria D; Riou O
Front Oncol; 2022; 12():842402. PubMed ID: 35356227
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
[TBL] [Abstract][Full Text] [Related]
8. Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed mycobacterium obuense (IMM-101) vaccination for non-progressive locally advanced pancreatic cancer, after induction chemotherapy with (modified)FOLFIRINOX - The LAPC-2 trial.
van 't Land FR; Latifi D; Moskie M; Homs MYV; Bosscha K; Bonsing BA; Mieog SD; van der Harst E; Coene PLO; Wijsman JH; van der Schelling GP; Groot Koerkamp B; Nuyttens JJ; van Eijck CHJ;
Radiother Oncol; 2023 Jun; 183():109541. PubMed ID: 36813171
[TBL] [Abstract][Full Text] [Related]
9. A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.
Parikh PJ; Lee P; Low DA; Kim J; Mittauer KE; Bassetti MF; Glide-Hurst CK; Raldow AC; Yang Y; Portelance L; Padgett KR; Zaki B; Zhang R; Kim H; Henke LE; Price AT; Mancias JD; Williams CL; Ng J; Pennell R; Pfeffer MR; Levin D; Mueller AC; Mooney KE; Kelly P; Shah AP; Boldrini L; Placidi L; Fuss M; Chuong MD
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(4):799-808. PubMed ID: 37210048
[TBL] [Abstract][Full Text] [Related]
10. Real-time Magnetic Resonance-guided Liver Stereotactic Body Radiation Therapy: An Institutional Report Using a Magnetic Resonance-Linac System.
Feldman AM; Modh A; Glide-Hurst C; Chetty IJ; Movsas B
Cureus; 2019 Sep; 11(9):e5774. PubMed ID: 31723533
[TBL] [Abstract][Full Text] [Related]
11. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
12. Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma.
Bouchart C; Engelholm JL; Closset J; Navez J; Loi P; Gökburun Y; De Grez T; Mans L; Hendlisz A; Bali MA; Eisendrath P; Van Gestel D; Hein M; Moretti L; Van Laethem JL
Ther Adv Med Oncol; 2021; 13():17588359211045860. PubMed ID: 34691244
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome.
Teriaca MA; Loi M; Suker M; Eskens FALM; van Eijck CHJ; Nuyttens JJ
Radiother Oncol; 2021 Feb; 155():232-236. PubMed ID: 33217500
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Body Radiotherapy as an Effective Treatment for Pancreatic Cancer.
Hurmuz P; Cengiz M; Ozyigit G; Yuce Sari S; Kahvecioglu A; Beduk Esen CS; Yalcin S; Zorlu F
Cureus; 2023 Apr; 15(4):e38255. PubMed ID: 37252548
[TBL] [Abstract][Full Text] [Related]
15. Consolidatory ablative stereotactic body radiation therapy after induction chemotherapy for unresectable pancreatic cancer: A single center experience.
Lee HI; Kang HC; Chie EK
Front Oncol; 2022; 12():974454. PubMed ID: 36505838
[TBL] [Abstract][Full Text] [Related]
16. MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC).
Pavic M; Niyazi M; Wilke L; Corradini S; Vornhülz M; Mansmann U; Al Tawil A; Fritsch R; Hörner-Rieber J; Debus J; Guckenberger M; Belka C; Mayerle J; Beyer G
Radiat Oncol; 2022 Jan; 17(1):18. PubMed ID: 35078490
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic MR-guided online adaptive radiotherapy reirradiation (SMART reRT) for locally recurrent pancreatic adenocarcinoma: A case report.
Doty DG; Chuong MD; Gomez AG; Bryant J; Contreras J; Romaguera T; Alvarez D; Kotecha R; Mehta MP; Gutierrez AN; Mittauer KE
Med Dosim; 2021 Winter; 46(4):384-388. PubMed ID: 34120803
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic Magnetic Resonance-Guided Daily Adaptive SABR (SMART) for Localised Non-Metastatic Pancreatic Cancer: First Reported Clinical Outcomes From the UK.
Nugent K; Mukherjee S; Teoh S; George B; Martin A; Gaya A; Aznar-Garcia L; Chu K; Robinson M; Maughan T; Good J
Clin Oncol (R Coll Radiol); 2024 May; ():. PubMed ID: 38902119
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
